A case of vanishing bile duct syndrome and IBD secondary to Hodgkin's lymphoma

Nature Clinical Practice Gastroenterology and Hepatology

Volumn 5, Issue 1, 2008, Pages 49-53

  DeBenedet, Anthony T ^a   Berg, Carl L ^b   Enfield, Kyle B ^c   Woodford, Randall L ^b   Bennett, Audrey K ^d   Northup, Patrick G ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

^d St Mary's Hospital Richmond   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; BUDESONIDE; CHLORMETHINE; DACARBAZINE; DEXAMETHASONE; VITAMIN K GROUP;

ADULT; ARTICLE; BILE DUCT DISEASE; CASE REPORT; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG SAFETY; ECHOGRAPHY; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENTERITIS; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LEUKOCYTE COUNT; LEUKOCYTOSIS; LIVER BIOPSY; LYMPH NODE BIOPSY; LYMPHADENOPATHY; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; VANISHING BILE DUCT SYNDROME;

ADULT; BILE DUCT DISEASES; HODGKIN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; SYNDROME;

EID: 38049075780     PISSN: 17434378     EISSN: 17434386     Source Type: Journal    
DOI: 10.1038/ncpgasthep1001     Document Type: Article

References (16)

1. Reese GE et al. (2006) Diagnostic precision of anti- Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Am J Gastroenterol 101: 2410-2422
2. Satsangi J et al. (2006) The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications. Gut 55: 749-753
3. Koren G et al. (1992) The effects of impaired liver function on the elimination of antineoplastic agents. Ann Pharmacother 26 363-371
4. Hubscher SG et al. (11993) Vanishing bile duct syndrome: A possible mechanism for intrahepatic cholestasis in Hodgkin's lymphoma. Hepatology 17: 70-77
5. Crosbie OM et al. (1997) Resolution of paraneoplastic bile duct paucity following successful treatment of Hodgkin's disease. Hepatology 26: 5-8
6. Cavalli G et al. (1979) Changes in the small biliary passages in the hepatic localization of Hodgkin's disease. Virchows Arch A Pathol Anat Histol 384: 295-306
7. Lefkowitch JH et al. (1985) Hepatic Hodgkin's disease simulating cholestatic hepatitiswith liver failure. Arch Pathol Lab Med 109: 424-426
8. Gottrand F et al. (1997) Intrahepatic cholestasis related to vanishing bile duct syndrome in Hodgkin's disease. J Pediatr Gastroenterol Nutr 24: 430-433
9. Yusuf MA et al. (2000) Jaundice caused by vanishing bile duct syndrome in a child with Hodgkin lymphoma. J Pediatr Hematol Oncol 22: 154-157
10. Loftus EV Jr et al. (2000) Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 95: 2308-2312
11. Lewis JD et al. (2001) Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 121: 1080-1087
12. Ramasamy KA et al. (2002) A case of primary non-Hodgkin's lymphoma of the transverse colon presenting as inflammatory bowel disease. Eur J Gastroenterol Hepatol 14: 1401-1403
13. Vincenzi B et al. (2001) Unusual presentation of Hodgkin's disease mimicking inflammatory bowel disease. Leuk Lymphoma 42: 521-526
14. Scheuer PJ (1998) Ludwig Symposium on biliary disorders-part II. Pathologic features and evolution of primary biliary cirrhosis and primary sclerosing cholangitis. Mayo Clin Proc 73: 179-183
15. Hamid S et al. (1997) Protracted cholestatic hepatitis after the use of prostata. Ann Intern Med 127: 169-170
16. Barta SK et al. (2006) Idiopathic cholestasis as a paraneoplastic phenomenon in Hodgkin's lymphoma. Clin Lymphoma Myeloma 7: 77-82